Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 12/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.59 |
| ▸ | GRIA4 | P48058 | 8/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189075 | 1.00 | GRIA2 (0.59) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2189078 | 1.00 | GRIA2 (0.59) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2188063 | 1.00 | GRIA2 (0.59) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2191010 | 0.92 | GRIA2 (0.59) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2188815 | 0.92 | GRIA2 (0.59) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2190200 | 0.92 | GRIA2 (0.59) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2186842 | 0.92 | GRIA2 (0.59) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2187976 | 0.87 | GRIA2 (0.55) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2187972 | 0.87 | GRIA2 (0.55) | GRIA2KCNH2GRIA4 | |
| SCHEMBL7951817 | 0.85 | GRIA2 (0.53) | GRIA2KCNH2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361246-A1 | OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS | Pfizer Inc. (US) | 2011-08-31 | — | — | EP | claimed |
| US-20110172297-A1 | Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2011-07-14 | — | — | US | claimed |
| WO-2010038167-A1 | OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS | PFIZER INC. (US) | 2010-04-08 | — | — | WO | claimed |
| EP-2361246-A1 | OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS | Pfizer Inc. (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110172297-A1 | Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2011-07-14 | — | — | US | disclosed |
| US-20110172297-A1 | Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2011-07-14 | — | — | US | disclosed |
| WO-2010038167-A1 | OXOPIPERIDINYL AND PYRANYL SULFONAMIDES AS AMPA POTENTIATORS | PFIZER INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172297-A1 | Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof | GRIK5, GABRE, GRIK2 | GRIA2 34/4885KCNH2 577/4885GRIA4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.